Scarffe J H, Anderson H, Palmer M K, Crowther D
Eur J Cancer Clin Oncol. 1983 Oct;19(10):1361-4. doi: 10.1016/0277-5379(93)90004-o.
Pretreatment serum beta 2m levels were estimated in 65 patients with multiple myeloma. After correction for changes in renal function, the level of beta 2m attributable to multiple myeloma (beta 2m-m) no longer correlated with the serum creatinine, but showed a strong correlation with the total body myeloma cell mass (P = 0.002). There was an inverse correlation between beta 2m-m and the Karnofsky performance status of patients at presentation (P = 0.001). Patients with a pretreatment beta 2m-m level of less than the median value of 2.94 mg/l survived significantly longer than those with a raised level (P = 0.0008).
对65例多发性骨髓瘤患者进行了治疗前血清β2微球蛋白水平评估。在对肾功能变化进行校正后，归因于多发性骨髓瘤的β2微球蛋白水平（β2m-m）不再与血清肌酐相关，但与全身骨髓瘤细胞量呈强相关（P = 0.002）。β2m-m与患者初诊时的卡氏功能状态呈负相关（P = 0.001）。治疗前β2m-m水平低于中位数2.94 mg/l的患者比水平升高的患者存活时间显著更长（P = 0.0008）。
